Hear+Now – An AI-Powered Audio Digest: When PBC Patients Outpace the Treatment Conversation
Reviewed by: HU Medical Review Board | Last reviewed: June 2026 | Last updated: June 2026
Modern clinicians often underestimate a patient's readiness for advanced clinical dialogue. Data reveals that individuals living with primary biliary cholangitis are independently researching advanced therapies and clinical trials long before failure occurs on standard therapy. To meet these proactive patients where they are, clinicians must look past current primary biliary cholangitis treatment guidelines that rely on reactive monitoring. Listen to this brief audio digest to discover how to seamlessly integrate second-line treatment options directly into your standard reassessment consultations.
This audio digest was generated with the assistance of an AI tool and reviewed by a member of our Editorial Team and Health Union Medical Review Board. This information is provided for general knowledge and is not a substitute for professional medical advice.
Transcript:
Speaker 1: Today, we're talking about primary biliary cholangitis and when patients outpace the treatment conversation with doctors.
Speaker 2: Right. And we're grounding this in data from the 2026 PBC In America survey, plus some broader chronic liver disease literature and health literacy.
Speaker 1: Right. So 63 percent of patients strongly agree that they actively seek information about the latest PBC treatment.
Speaker 2: Which is a lot.
Speaker 1: Yeah, and 68 percent want to know about treatments and treatment options. 65 percent are looking into related conditions and complications, and 53 percent are digging into symptom management.
Speaker 2:So they're doing their homework.
Speaker 1: Exactly. So here is the question for clinicians listening. If patients are independently researching this heavily, are standard clinic visits underestimating their readiness for an advanced clinical dialogue?
Speaker 2: They could be. Because if you look at the clinical management breakdown, 48 percent of patients are managed by a hepatology specialist. And 35 percent by a gastroenterologist. So they're seeing the specialists. But despite that specialist care, patients are reporting significant barriers. 30 percent state current treatments just do not fully manage their symptoms. Additionally, 35 percent feel not enough research is being done, while 20 percent report simply not knowing enough about their treatment options.
Speaker 1: It sounds like clinicians may be keeping patients in the waiting room of standard care when they're already, you know, knocking on the laboratory door...88 percent of respondents said they would participate in or at least consider a clinical trial.
Speaker 2: And it's important again to recognize that patients are independently researching alternative therapies. That could mean they are ready for a second-line treatment or clinical trial conversation long before the provider actually initiates it. Drawing on the broader chronic liver disease literature, we also know that proactive health communication is essential for shared decision-making.
Speaker 1: So how should this alter the timing of these clinical conversations? Because you know in a standard consult it's hard to justify derailing the visit if they haven't failed first-line therapy yet.
Speaker 2: Right, and guidelines recommend a 12-month reassessment of treatment response to the standard first-line treatment.
Speaker 1: Ursodiol. Right, the standard check-in.
Speaker 2: Exactly. But treating that 12-month mark just as a pass or fail test could be a missed opportunity. Instead of waiting for treatment failure, clinicians could proactively map out next steps.
Speaker 1: Like introducing second-line options early.
Speaker 2: Yes. Introduce those second-line options and drug classes early. Things like P PAR agonists or IBAT inhibitors.
Speaker 1: So integrating this information really shifts the consultation from reactive monitoring to proactive planning.
Speaker 2: Right. Clinicians do not need to wait for patients to vocalize treatment fatigue. You can leverage their existing information-seeking behavior, and integrate second-line treatment options and clinical trial parameters into their standard 12-month Ursodiol reassessment.
Speaker 1: Yeah. Which totally changes the clinic dynamic. We leave you with this thought. If your patients are already this proactive about researching clinical trials and treatments, how can you meet them where they are and be proactive about sharing next steps before the patient even asks about them?